ロード中...
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
BACKGROUND: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generation ALK TKIs. METHODS: We analyzed 106 plasma spec...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6858956/ https://ncbi.nlm.nih.gov/pubmed/31358542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1436 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|